Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerDr. Reddy's Laboratories

Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market

Auto-immuneGastroenterology

Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development

CancerNASDAQ: PNT

Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio

ADC / XDCFinance

Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing

Show More